Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 352.38M | 348.88M | 321.48M | 267.84M | 258.62M | 248.23M |
Gross Profit | 288.54M | 288.81M | 266.84M | 219.53M | 215.33M | 208.90M |
EBITDA | 54.95M | 64.34M | 40.52M | -10.69M | -1.89M | -45.76M |
Net Income | 40.18M | 42.42M | 67.44M | -30.20M | -10.29M | -49.28M |
Balance Sheet | ||||||
Total Assets | 270.42M | 263.92M | 239.05M | 171.43M | 187.93M | 202.03M |
Cash, Cash Equivalents and Short-Term Investments | 106.43M | 104.42M | 82.00M | 65.95M | 87.08M | 95.81M |
Total Debt | 18.66M | 24.84M | 48.10M | 48.59M | 48.13M | 47.70M |
Total Liabilities | 67.64M | 70.81M | 96.33M | 189.42M | 187.85M | 202.18M |
Stockholders Equity | 202.78M | 193.11M | 142.72M | -17.99M | 82.00K | -150.00K |
Cash Flow | ||||||
Free Cash Flow | 68.32M | 64.52M | 24.79M | -20.58M | -5.45M | -34.82M |
Operating Cash Flow | 67.55M | 66.20M | 26.77M | -17.89M | -1.98M | -30.26M |
Investing Cash Flow | -3.96M | -9.58M | -2.15M | -2.66M | -3.40M | -4.55M |
Financing Cash Flow | -3.61M | -34.20M | -8.57M | -580.00K | -3.35M | 61.56M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $985.17M | 24.18 | 16.62% | ― | 6.85% | -67.67% | |
63 Neutral | $1.01B | ― | -36.26% | ― | 127.33% | 21.31% | |
55 Neutral | $1.60B | ― | -188.03% | ― | -11.42% | 0.26% | |
53 Neutral | $1.87B | ― | -57.19% | ― | -0.33% | -3.59% | |
52 Neutral | $975.09M | ― | -51.85% | ― | 11070.12% | 32.07% | |
51 Neutral | $7.30B | 0.27 | -62.71% | 2.44% | 15.02% | 0.60% | |
49 Neutral | $1.46B | ― | -23.20% | ― | 24.49% | 5.14% |
MiMedx Group announced record financial results for the second quarter of 2025, with net sales reaching $99 million, a 13% increase from the previous year. The company achieved its highest quarterly net sales, driven by growth in its Wound and Surgical franchises, and reported a net income of $10 million. MiMedx also raised its net sales growth expectations for 2025, anticipating low double-digit growth. The company is engaging with CMS on proposed reimbursement reforms for skin substitutes, which could impact future operations and market positioning.
The most recent analyst rating on (MDXG) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on MiMedx Group stock, see the MDXG Stock Forecast page.
On June 18, 2025, MiMedx Group held its Annual Meeting of Shareholders, where 85.7% of the voting shares were represented. During the meeting, nine directors were re-elected, an advisory resolution on executive compensation was approved, Deloitte & Touche LLP was ratified as the independent auditor for 2025, an amendment to the 2016 Equity and Cash Incentive Plan was approved, and it was decided that the advisory vote on executive compensation would occur annually.
The most recent analyst rating on (MDXG) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on MiMedx Group stock, see the MDXG Stock Forecast page.
MiMedx Group announced its participation in the Bank of America Securities 2025 Healthcare Conference, highlighting its updated investor presentation. The company is poised for growth with expectations of expanding its product portfolio and increasing its presence in surgical settings, driven by favorable market trends and innovative placental-derived products. The announcement underscores MiMedx’s strategic focus on expanding its global footprint and enhancing its product offerings to drive profitability and stakeholder value.
The most recent analyst rating on (MDXG) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on MiMedx Group stock, see the MDXG Stock Forecast page.